A Study of PF-07258669 In Healthy Adult Participants
Status:
Not yet recruiting
Trial end date:
2022-07-20
Target enrollment:
Participant gender:
Summary
Part A of this study is to evaluate safety, tolerability, and pharmacokinetics (PK) of
PF-07258669 after administration of multiple ascending oral doses to healthy adult
participants. A cohort of healthy adult Japanese participants may also be evaluated. Part B
of this study is a 2-period, fixed-sequence, multiple-dose, open-label design to evaluate the
effect of PF-07258669 on midazolam PK in healthy adult participants. Part B will be conducted
if the results of Part A support further evaluation of PF-07258669.